Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Prebet

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Oncotarget|November 16, 2017
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapyThomas Prebet, Thomas Cluzeau, Sophie Park, et al.
British Journal of Haematology|November 19, 2015
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup studyThomas Prebet, Zhuoxin Sun, Rhett P Ketterling, et al.
Blood|June 19, 2010
The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcomeThomas Prebet, Anne-Catherine Lhoumeau, Christine Arnoulet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905Thomas Prebet, Zhuoxin Sun, Maria E Figueroa, et al.
Plos One|May 12, 2015
Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal CancerAnne-Catherine Lhoumeau, Sébastien Martinez, Jean-Marie Boher, et al.
Oncotarget|April 16, 2016
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemiaNorbert Vey, Jacques Delaunay, Giovanni Martinelli, et al.
Leukemia Research|August 9, 2012
PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patientsCecile Borel, Nicole Dastugue, Valérie Cances-Lauwers, et al.
Blood|July 10, 2014
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML IntergroupMarie-Anne Hospital, Thomas Prebet, Sarah Bertoli, et al.
Haematologica|February 26, 2015
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trialNicolas Boissel, Aline Renneville, Thibaut Leguay, et al.
Haematologica|December 18, 2009
Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des MyelodysplasiesCharikleia Kelaidi, Aspasia Stamatoullas, Odile Beyne-Rauzy, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Oncotarget|November 16, 2017
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapyThomas Prebet, Thomas Cluzeau, Sophie Park, et al.
British Journal of Haematology|November 19, 2015
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup studyThomas Prebet, Zhuoxin Sun, Rhett P Ketterling, et al.
Blood|June 19, 2010
The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcomeThomas Prebet, Anne-Catherine Lhoumeau, Christine Arnoulet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905Thomas Prebet, Zhuoxin Sun, Maria E Figueroa, et al.
Plos One|May 12, 2015
Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal CancerAnne-Catherine Lhoumeau, Sébastien Martinez, Jean-Marie Boher, et al.
Oncotarget|April 16, 2016
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemiaNorbert Vey, Jacques Delaunay, Giovanni Martinelli, et al.
Leukemia Research|August 9, 2012
PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patientsCecile Borel, Nicole Dastugue, Valérie Cances-Lauwers, et al.
Blood|July 10, 2014
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML IntergroupMarie-Anne Hospital, Thomas Prebet, Sarah Bertoli, et al.
Haematologica|February 26, 2015
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trialNicolas Boissel, Aline Renneville, Thibaut Leguay, et al.
Haematologica|December 18, 2009
Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des MyelodysplasiesCharikleia Kelaidi, Aspasia Stamatoullas, Odile Beyne-Rauzy, et al.
Pageof 10